New Day Diagnostics

New Day Diagnostics is an emerging, vertically integrated diagnostics company with a dual-pronged business model. It commercially offers ColoHealth, a blood-based test for colorectal cancer (CRC) screening with a validated 99.7% Negative Predictive Value (NPV), and provides diagnostic Contract Research Organization (CRO) services to other developers. The company is pursuing aggressive growth through strategic mergers, like EDP Biotech, and partnerships to expand its commercial footprint and pipeline into other cancers and infectious diseases. Its operations are supported by a CLIA-certified, ISO 13485-accredited laboratory, underpinning both its product commercialization and service offerings.

Liquid biopsy platform for detecting disease biomarkers from a blood sample. Supports both proprietary test development and end-to-end diagnostic CRO services, anchored by a CLIA-certified, ISO 13485-accredited laboratory.

New Day operates in the highly competitive liquid biopsy and early cancer detection space, competing directly with companies like Guardant Health (Shield test) and Exact Sciences (Cologuard, multi-cancer detection efforts). Its CRO services compete with large, global CROs and specialized diagnostic development firms. Its success depends on demonstrating superior convenience, accuracy, and cost-effectiveness.